```json
{
"content": [
{
"type": "paragraph",
"content": "The Intracranial Aneurysm Consumables market encompasses medical devices and materials used in the diagnosis and treatment of cerebral aneurysms, including embolic coils, flow diverters, and neurovascular stents. As a critical segment of the neurointerventional sector, this market is driven by the rising incidence of cerebrovascular disorders and advancements in minimally invasive therapies. The Intracranial Aneurysm Consumables market size is projected to expand at a robust CAGR during the forecast period (2026–2033), reflecting strong growth potential and strategic opportunities for stakeholders. Key macro drivers include the global shift toward outpatient procedures, aging populations, and enhanced reimbursement policies in high-income regions."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["Detachable Coils", "Flow Diverters", "Neurovascular Stents"],
"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[1,200, 1,320, 1,450, 1,580, 1,700, 1,830, 2,000, 2,150, 2,300, 2,450, 2,600, 2,750, 2,900],
[800, 850, 900, 950, 1,000, 1,100, 1,200, 1,320, 1,450, 1,600, 1,750, 1,900, 2,050],
[500, 520, 550, 580, 610, 650, 700, 750, 800, 850, 900, 950, 1,000]
]
}
},
{
"type": "paragraph",
"content": "According to recent industry analysis, the global Intracranial Aneurysm Consumables market reached an estimated value of $1.2 billion in 2025, with North America dominating the industry due to early adoption of advanced technologies and a well-established healthcare infrastructure. The market forecast highlights a CAGR of 6.5% through 2033, fueled by innovations in bioabsorbable materials and AI-driven interventional tools. Regulatory harmonization under frameworks like ISO 13485 is streamlining approvals, while Asia-Pacific remains the fastest-growing region, driven by improving vascular care accessibility and rising surgical volumes. Strategic partnerships among device manufacturers and academic institutions are further accelerating product differentiation and clinical validation."
}
]
}
```
